Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesStepped-Dose vs. Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events: A Randomized Trial
Annals of Internal Medicine, 07/07/09
Gutierrez-Valencia A et al. - Efavirenz is a powerful component of effective highly active antiretroviral therapy. Unfortunately, about half of patients develop disturbing neuropsychiatric side effects. Although side effects will subside for many patients as they continue to take the drug, other patients have to stop taking efavirenz. This randomized trial compared full-dose efavirenz to stepped-dose efavirenz during the first 2 weeks of treatment and found fewer side effects during the first week in patients on stepped-dose therapy. After 24 weeks, HIV-RNA levels and CD4+ cell counts were similar in both groups. A stepwise dose of efavirenz over 2 weeks reduces the incidence and intensity of efavirenz-related NPAEs while maintaining efficacy.
Related Articles
Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children
Antimicrobial Agents and Chemotherapy, 10/08/09
Relevance Score: 83%
Today in Adverse Drug Reactions...keeping you current
Receive free subspecialty "5-minute updates" via email
In vitro detection and characterization of drug hypersensitivity using flow cytometry
Allergy, 12/16/09
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Journal of the National Cancer Institute, 12/15/09
A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient
Urologia Internationalis, 12/14/09
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhibition of Herpes Simplex Virus Type 1 By the Experimental Immunosuppressive Agent Leflunomide
Transplantation, 12/16/09
Use of oseltamivir in children
Canadian Family Physician, 12/16/09
The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Clopidogrel Hypersensitivity: A Novel Multi-Day Outpatient Oral Desensitization Regimen
Annals of Pharmacotherapy, 12/16/09
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia
Current Medical Research and Opinion, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor